Pharmacokinetic-Directed High-Dose Busulfan Combined with Cyclophosphamide and Etoposide Results in Predictable Drug Levels and Durable Long-Term Survival in Lymphoma Patients Undergoing Autologous Stem Cell Transplantation

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 8, 2012, Pages 1287-1294

  Zhang, Hongzheng ^a   Graiser, Michael ^a   Hutcherson, Donald A ^a   Dada, M Olufemi ^a   McMillan, Stephanie ^a   Ali, Zahir ^a   Flowers, Christopher R ^a   Waller, Edmund K ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autologous hematopoietic cell transplantation; Intravenous; Lymphoma; Oral busulfan; Overall survival

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; ETOPOSIDE;

ADULT; AREA UNDER THE CURVE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; HUMAN; LONG TERM SURVIVAL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORTALITY; NEUROTOXICITY; RETROSPECTIVE STUDY; VEIN OCCLUSION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BUSULFAN; COHORT STUDIES; CYCLOPHOSPHAMIDE; DRUG ADMINISTRATION ROUTES; ETOPOSIDE; FEMALE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS;

EID: 84864017925     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2012.02.006     Document Type: Article

References (23)

1. Ciurea S.O., Andersson B.S. Busulfan in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2009, 15:523-536.
2. Madden T., de Lima M., Thapar N., et al. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant 2007, 13:56-64.
3. Copelan E.A. Hematopoietic stem-cell transplantation. N Engl J Med 2006, 354:1813-1826.
4. Kline R.M., Meiman S., Tarantino M.D., Herzig R.H., Bertolone S.J. A detailed analysis of charges for hematopoietic stem cell transplantation at a children's hospital. Bone Marrow Transplant 1998, 21:195-203.
5. Hiddemann W., Buske C., Dreyling M., et al. Treatment strategies in follicular lymphomas: current status and future perspectives. J Clin Oncol 2005, 23:6394-6399.
6. Lonial S., Hicks M., Rosenthal H., et al. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products. Biol Blood Marrow Transplant 2004, 10:848-857.
7. Jones R.J., Lee K.S., Beschorner W.E., et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987, 44:778-783.
8. Cheson B.D., Horning S.J., Coiffier B., et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17:1244.
9. Bowden R.J., Turkington D.A. Instrumental variables 1984, Cambridge University Press, Cambridge, MA.
10. Greene W. Endogeneity and instrumental variable estimation. Econometric Analysis 2003, 80-83. Prentice Hall, New York.
11. Newhouse J.P., McClellan M. Econometrics in outcomes research: the use of instrumental variables. Annu Rev Public Health 1998, 19:17-34.
12. Terza J.V., Basu A., Rathouz P.J. Two-stage residual inclusion estimation: addressing endogeneity in health econometric modeling. J Health Economics 2008, 27:531-543.
13. Aggarwal C., Gupta S., Vaughan W.P., et al. Improved outcomes in intermediate- and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan, cyclophosphamide, and etoposide preparative regimen. Biol Blood Marrow Transplant 2006, 12:770-777.
14. Dean R.M., Pohlman B., Sweetenham J.W., et al. Superior survival after replacing oral with intravenous busulfan in autologous stem cell transplantation for non-Hodgkin lymphoma with busulfan, cyclophosphamide and etoposide. Br J Haematol 2010, 148:226-234.
15. Hassan M., Ljungman P., Bolme P., et al. Busulfan bioavailability. Blood 1994, 84:2144-2150.
16. McCune J.S., Holmberg L.A. Busulfan in hematopoietic stem cell transplant setting. Expert Opin Drug Metab Toxicol 2009, 5:957-969.
17. Kim J.G., Sohn S.K., Chae Y.S., et al. Multicenter study of intravenous busulfan, cyclophosphamide, and etoposide (i.v. Bu/Cy/E) as conditioning regimen for autologous stem cell transplantation in patients with non-Hodgkin's lymphoma. Bone Marrow Transplant 2007, 40:919-924.
18. Mounier N., Canals C., Gisselbrecht C., et al. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 2011 Oct 17, [Epub ahead of print].
19. Ryu S.G., Lee J.H., Choi S.J., et al. Randomized comparison of four-times-daily versus once-daily intravenous busulfan in conditioning therapy for hematopoietic cell transplantation. Biol Blood Marrow Transplant 2007, 13:1095-1105.
20. Wadehra N., Farag S., Bolwell B., et al. Long-term outcome of Hodgkin disease patients following high-dose busulfan, etoposide, cyclophosphamide, and autologous stem cell transplantation. Biol Blood Marrow Transplant 2006, 12:1343-1349.
21. Shenoy P.J., Malik N., Nooka A., et al. Racial differences in the presentation and outcomes of diffuse large B-cell lymphoma in the United States. Cancer 2010, 117:2530-2540.
22. Wilkinson G.R. Drug metabolism and variability among patients in drug response. N Engl J Med 2005, 352:2211-2221.
23. Joshua T.V., Rizzo J.D., Zhang M.J., et al. Access to hematopoietic stem cell transplantation: effect of race and sex. Cancer 2010, 116:3469-3476.